Business
SciBase resolves on a directed share issue of approximately SEK 11 million
The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company on 16 June 2025, pursuant to the authorisation granted by the annual general meeting held on 17 June 2025, resolved on a new share issue, with deviation from the existing shareholders' preferential rights, of approximately SEK 11 million to Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB (the "Directed Issue II", and, tog
About this update from Scibase Holding Ab
[{"type":"text","content":"STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company on 16 June 2025, pursuant to the authorisation granted by the annual general meeting held on 17 June 2025, resolved on a new share issue, with deviation from the existing shareholders' preferential rights, of approximately SEK 11 million to Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Ribbskottet AB (the "Directed Issue II", and, together with the directed issue to Castle Biosciences (the "Directed Issue I"), the "Directed Issues").","length":701,"tagName":"p"},{"type":"text","content":"THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTION IS WHOLLY OR PARTLY SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO SECTION "IMPORTANT INFORMATION" BELOW.","length":477,"tagName":"p"},{"type":"text","content":"Background and motives","length":22,"tagName":"p"},{"type":"text","content":"SciBase is a medical technology company specializing in early detection and prevention in dermatology through the commercialization of Nevisense. Nevisense is a patient-centric platform that combines AI (artificial intelligence) and advanced EIS (electrical impedance spectroscopy) technology to increase diagnostic accuracy and thereby ensure the prevention of skin diseases. By enabling doctors to make accurate diagnoses with greater precision, subsequent healthcare interventions can be initiated more quickly, improving the outlook for patients with serious conditions such as skin cancer.","length":594,"tagName":"p"},{"type":"text","content":"SciBase has launched Nevisense in the US, which accounts for about three-quarters of the estimated market potential, and is therefore investing in establishing Nevisense as the industry standard. As part of this, the organization in the US subsidiary has been strengthened with several new sales resources and is now represented in five regions that sup...